These observations have been further confirmed in the context of a pooled analysis of six randomized clinical trials including 3771 BC patients receiving neoadjuvant combination chemotherapy, where the authors reported significantly higher proportions of primary tumors with high TILs (≥60%) among TNBC (30%) and HER2+ (~20%) BC patients, as compared to the luminal-like carcinoma subgroup (13%) [8]. Here, ERBB2 is linked to breast cancer.